Last reviewed · How we verify
NCT05335538: TTIPS
TruGraf and TRAC In Pediatrics Study
trial testing Patients monitored with TruGraf and TRAC testing in Kidney Transplant Rejection in 75 participants. Status unknown.
30 December 2022
Quick facts
| Lead sponsor | Transplant Genomics, Inc. |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 75 |
| Start date | 30 November 2021 |
| Primary completion | 30 December 2022 |
| Estimated completion | 1 March 2023 |
| Sites | 3 locations across Canada, United States |
Drugs / interventions tested
- Patients monitored with TruGraf and TRAC testing
Conditions studied
- Kidney Transplant Rejection — all drugs for Kidney Transplant Rejection →
Sponsor
Transplant Genomics, Inc. — full company profile →
Who can join
Adults 1 to 18, any sex, with Kidney Transplant Rejection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a pilot 3 center prospective study of pediatric renal kidney recipients undergoing protocol biopsies examining the performance of the TruGraf gene expression test in children and adolescents.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05335538
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Kidney Transplant Rejection
Currently open trials in the same condition.
- NCT07412470 — A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantati · Phase 2, PHASE3 · recruiting
- NCT07053462 — CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk · Phase 1, PHASE2 · recruiting
- NCT06564649 — PROACT Pilot Trial · active not recruiting
- NCT07006532 — Treatment of Chronic Active Antibody Mediated Rejection With Tocilizumab · NA · recruiting
- NCT07275541 — Platelet Aggregation in the Diagnosis of Acute Graft Rejection · recruiting
Other Transplant Genomics, Inc. trials
Trials by the same sponsor.
- NCT07393594 — ID-ENTITY Trial- Evaluating Serial T-ID Monitoring · not yet recruiting
- NCT07231328 — PIONEER Trial (Post-Transplant Application of TruGraf and TRAC Molecular Panel in Renal Transplant Recipients) · not yet recruiting
- NCT04670926 — Immunosuppression Management in Renal Transplant Recipients With Transplant Excellence Based on TruGraf Test · NA · unknown
- NCT04267016 — Acceptability and Feasibility of TruGraf® Testing as Part of the Standard of Care · terminated
- NCT04398498 — Molecular Biomarkers in Renal Transplantation Via TruGraf® Test · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05335538 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Transplant Genomics, Inc.
- Last refreshed: 19 April 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05335538.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing